TY - JOUR
T1 - Tobacco dependence treatment for special populations
T2 - Challenges and opportunities
AU - Castaldelli-Maia, João M.
AU - Harutyunyan, Arusyak
AU - Herbec, Aleksandra
AU - Kessel, Tzvia
AU - Odukoya, Oluwakemi
AU - Kemper, Katherine E.
AU - Hays, J. T.
AU - Vardavas, Constantine
N1 - Funding Information:
The protected time for the contribution of JMC-M, AHarutyunyan, AHerbec, TK, OO, KEK, JTH, and CV towards the research reported in this publication has been supported by Pfizer Independent Grants for Learning and Change (IGLC 25629313, PI: Castaldelli-Maia; IGLC 25670019, PI: Harutyunyan; IGLC 25672387, PI: Zatonski; IGLC 25782443, PI: Valinsky; IGLC 13503941, PI: Odukoya; IGLC 13106933, PI: Loghin; IGLC 12581469, PI: Hurt; IGLC 24026663, PI: Hays).
Funding Information:
The protected time for the contribution of OO towards the research reported in this publication was also supported by the Fogarty International Center of the National Institutes of Health (award K43TW010704). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All of the authors have participated in a global collaboration to advance tobacco dependence treatment, the Global Bridges Healthcare Alliance for Tobacco Dependence Treatment at Mayo Clinic, U.S. Disclosure The protected time for the contribution of JMC-M, AHarutyunyan, AHerbec, TK, OO, KEK, JTH, and CV towards the research reported in this publication has been supported by Pfizer Independent Grants for Learning and Change (IGLC 25629313, PI: Castaldelli-Maia; IGLC 25670019, PI: Harutyunyan; IGLC 25672387, PI: Zatonski; IGLC 25782443, PI: Valinsky; IGLC 13503941, PI: Odukoya; IGLC 13106933, PI: Loghin; IGLC 12581469, PI: Hurt; IGLC 24026663, PI: Hays).
Funding Information:
The protected time for the contribution of OO towards the research reported in this publication was also supported by the Fogarty International Center of the National Institutes of Health (award K43TW010704). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. All of the authors have participated in a global collaboration to advance tobacco dependence treatment, the Global Bridges Healthcare Alliance for Tobacco Dependence Treatment at Mayo Clinic, U.S.
Publisher Copyright:
© 2021, Associacao Brasileira de Psiquiatria. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Although smoking rates have declined in most of the countries in the world, there are population groups within these countries whose smoking rates remain significantly higher than the general population. These ‘‘forgotten groups’’ who have not been receiving the needed attention in tobacco control policies and tobacco cessation efforts include people with serious mental illness, substance use disorders, tuberculosis, people living with human immunodeficiency virus (HIV), lesbian-gaybisexual-transgender-queer people, and pregnant women. A number of steps are needed at the national level in countries where these disparities exist, including modifications to national smoking cessation treatment guidelines that address the special needs of these populations, as well as targeted smoking cessation research, since these populations are often not included in clinical trials. Because of the higher smoking prevalence in these populations, as well as their lower smoking cessation treatment success rates than the general population, more resources are needed if we are to reduce health disparities in these vulnerable populations. Additionally, we believe that more effort should be focused on integrating smoking cessation treatment in the specialized care settings frequented by these subpopulations.
AB - Although smoking rates have declined in most of the countries in the world, there are population groups within these countries whose smoking rates remain significantly higher than the general population. These ‘‘forgotten groups’’ who have not been receiving the needed attention in tobacco control policies and tobacco cessation efforts include people with serious mental illness, substance use disorders, tuberculosis, people living with human immunodeficiency virus (HIV), lesbian-gaybisexual-transgender-queer people, and pregnant women. A number of steps are needed at the national level in countries where these disparities exist, including modifications to national smoking cessation treatment guidelines that address the special needs of these populations, as well as targeted smoking cessation research, since these populations are often not included in clinical trials. Because of the higher smoking prevalence in these populations, as well as their lower smoking cessation treatment success rates than the general population, more resources are needed if we are to reduce health disparities in these vulnerable populations. Additionally, we believe that more effort should be focused on integrating smoking cessation treatment in the specialized care settings frequented by these subpopulations.
KW - HIV
KW - Nicotine
KW - Pregnancy
KW - Smoking
KW - Tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85100835803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100835803&partnerID=8YFLogxK
U2 - 10.1590/1516-4446-2019-0782
DO - 10.1590/1516-4446-2019-0782
M3 - Article
C2 - 32491035
AN - SCOPUS:85100835803
SN - 1516-4446
VL - 43
SP - 75
EP - 82
JO - Revista Brasileira de Psiquiatria
JF - Revista Brasileira de Psiquiatria
IS - 1
ER -